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The 2016 Lasker-DeBakey Clinical Medical Research 
Award was given to three scientists working on different 
stages of the translational sciences on bringing a high effi-
cacious therapy against hepatitis C virus (HCV) infection to 
a reality. An effective treatment of HCV chronic infection 
was developed, by a team led by Michael Sofia, using a 
prodrug approach and the drug PSI-7977 or Sofosbuvir was 
approved in 2013 less than 28 years after the initial discov-
ery of HCV. This breakthrough was enabled by the availa-
bility of the subgenomic HCV replication system, devel-
oped by Charles Rice and Ralf Bartenschlager in 1999. The 
clinically proven Sofosbuvir with remarkable safety and 
efficacy was designed to enter the hepatocytes readily and 
to be processed upon cell entry to a triphosphate derivative, 
becoming a fully activated competitive and high affinity 
inhibitor for the HCV NS5B, an RNA-dependent RNA 
polymerase.  
While hepatitis diseases as a whole still pose a major 
public health issue globally, according to a WHO report 
(WHO reference number: WHO/HIV/2016.06, Global 
health sector strategy on viral hepatitis, 20162021)  
(http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/))  
the past few years has witnessed a major breakthrough in 
the antiviral treatment therapy for hepatitis C. HCV is one 
of the two viruses, B and C, for causing significant disease 
burden globally due to the progression to liver cirrhosis or 
cancers. It culminated recently with Charles Rice and Ralf 
Bartenschlager, together with Michael Sofia, winning the 
2016 Lasker-DeBakey Clinical Medical Research Award. 
The discoveries of Rice and Bartenschlager led to the de-
velopment of functional HCV replicons. Sofia harnessed the 
power of this newly available tool of “live HCV in the lab” 
for identification and improvement of anti-HCV drugs, 
leading to the development of a novel molecule using a 
prodrug approach, now known as Sofosbuvir (PSI-7977).  
The milestones in HCV virology and in antiviral drug 
development are illustrated in Figure 1. The 2016 Lasker 
Award represents the second time of Lasker Award series 
recognizing achievement in the HCV field with the 2000 
Lasker award on the initial discovery of HCV and the de-
velopment of screening methods that reduced the risk of its 
transmission.   
BRINGING HCV TO LIFE IN THE LAB: 
FUNCTIONAL HCV REPLICONS 
HCV was the first virus ever discovered by molecular clon-
ing technology in 1989; till then it was grouped in as non-A, 
non-B hepatitis viruses. The 2016 Lasker Award recognizes 
the work of Rice and Bartenschlager on the development of 
HCV replicons in 1999. With the live HCV system estab- 
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Figure 1  Timeline and milestone in hepatitis C virus (HCV) virology and targeted antiviral drug development. The roles of the 2016 Lasker Awardees, 
Bartenschlager, Rice, and Sofia, are illustrated. The 2000 Albert Lasker Clinical Medical Research Award was given to Michael Houghton of Chiron and 
Harvey Alter of NIH for their discovery of HCV (in 1989). 
lished in the lab, the viral replication, pathogenesis, and 
evolution in culture can now be studied with a viable in 
vitro replication system. Functional replicons also enabled 
the assay development for antiviral drug development. 
Before he worked on HCV, Rice was trained in molecu-
lar virology of Flavivirus. His first HCV paper was pub-
lished in 1993 on Journal of Virology (Grakoui et al., 1993). 
Since then, he began to shift his research focus to HCV 
field. His early studies focused on dissecting HCV gene 
expression and characterizing different viral proteins. In 
1996, the Rice Lab determined the conserved 3'-terminal 
sequence of HCV genomic RNA (Kolykhalov et al., 1996). 
This finding provided correct terminal sequences that are 
critically important for recovery of infectious HCV cDNA 
clone. All previous efforts on making replicons had failed 
due to the absence of the unanticipated ending sequence. In 
1997, the Rice Lab demonstrated that transferring of HCV 
RNA transcripts derived from full-length cDNA clone into 
the liver of chimpanzee could successfully cause HCV in-
fection and liver disease (Kolykhalov et al., 1997). This 
finding enabled the design and generation of a functional 
virus in lab. In 1999, Bartenschlager reported the successful 
replication of HCV genomic RNA in a human hepatoma 
cell line Huh7 (Lohmann et al., 1999). However, the initial 
system was not efficient for in vitro HCV replication. Sub-
sequently, the Rice Lab identified several adaptive muta-
tions in the HCV nonstructural protein NS5A. The new 
constructs conferred much increased replicative ability in 
vitro, as reported in 2000 (Blight et al., 2000). Continued 
search on HCV isolates with high in vitro replication effi-
ciency yielded the most famous HCV cDNA clone, JFH-1 
(genotype 2a). JFH-1 was isolated from a fulminant hepati-
tis patient by Takaji Wakita (Tokyo Metropolitan Institute 
of Neuroscience) in 2001 (Kato et al., 2001), exhibiting 
high efficient replication capability without additional adap-
tive mutations (Kato et al., 2003). In 2005, studies from 
Rice and Wakita were simultaneously published to demon-
strate the recombinant HCV virus derived from JFH-1 or 
chimeric genomes based on JFH-1 backbone were infec-
tious in Huh7 cells (Lindenbach et al., 2005; Wakita et al., 
2005). Confirmatory reports from various groups worldwide 
all corroborated the JFH-1 based replicons are robust in 
vitro replication systems supporting complete life cycle of 
HCV in cell culture.  
Another 2016 Lasker Awardee Bartenschlager (and his 
group) first described the selectable sub-genomic HCV 
RNA replicon in Science (Lohmann et al., 1999), a 
well-recognized milestone of in HCV cell models. Being a 
new comer to HCV academic field, Bartenschlager was at 
the University of Mainz in 1999. Prior to this academic po-
1200 Zhao, Q., et al.   Sci China Life Sci   November (2016) Vol.59 No.11 
sition, Bartenschlager had finished his PhD at the Center for 
Molecular Biology in Heidelberg (working on HBV) and 
his post-doctoral training at Hoffmann-La Roche (working 
on HCV proteases). Establishing an efficient HCV replicon 
model had been a goal for years for his group as well as for 
the Rice group. The replicon was developed by the transfec-
tion of the novel abicistronic selectable sub-genomic HCV 
RNA construct into a human hepatoma cell line Huh-7. 
They constructed the replicon by introducing a selectable 
marker, the neomycin phosphotransferase gene, driven by 
the HCV internal ribosomal entry site, and the HCV 
non-structural proteins (NS3-NS5B) are expressed from an 
encephalomyocarditis virus internal ribosomal entry site.  
TERMINATING HCV INFECTION IN 
PATIENTS: DEVELOPMENT OF SOFOSBUVIR 
Up to 2012, the best therapeutic regimen was concomitant 
use of pegylated interferon and ribavirin (or PR regimen). 
With a 24- or 48-week treatment cycle, the cure rate was 
40%50% with higher cure rate or SVR (Sustained Viro-
logic Response, Figure 1) of 50%80% for viral genotype 2 
and 3 but was less effective for genotype 1. Therefore, ef-
forts continue with the aim to search more effective antivi-
ral drugs with broader genotype coverage and with fewer 
side effects. One combination, PSI-7797 Sofosbuvir 
(Sovaldi®, Gilead Sciences, developed by a team led by 
Sofia) (Sofia et al., 2010) in combination with ribavirin was 
able to remarkably shorten the treatment cycle to 12 weeks 
with the cure rate of 80%95% (Gane et al., 2013).  
PSI-7977 was developed based on PSI-6130, a potent an-
tiviral compound. It inhibits the viral RNA replication in a 
competitive manner by binding to the RNA polymerase 
NS5B, thus effectively suppressing the viral replication in 
vitro  (Stuyver et al., 2006). Due to the poor bioavailability 
of PSI-6130, the therapeutic effect when tested clinically 
was not desirable. Sofia and colleagues developed a prodrug 
version of PSI-6130 which could enter hepatocytes more 
efficiently. PSI-7977 was designed to enter the hepatocytes 
readily and then being metabolized into its monophosphate 
derivative. A further in cell phosphorylation reaction would 
convert the compound into a triphosphate derivative, which 
is a potent viral replication inhibitor. The potent antiviral 
effects were demonstrated in the HCV replicon system 
(Stuyver et al., 2003), as well as during early phase clinical 
trials (Figure 1). 
This prodrug version, PSI-7977, with remarkable clinical 
performance in efficacy and safety, was approved in 2013 
by USFDA with a commercial name of Sofosbuvir. The 
performance of Sofosbuvir when used alone was just as 
remarkable, making the combination therapy with interferon 
or ribavirin optional. High cure rates were observed for pa-
tients with different genotypes with no drug resistance. Up 
to now, approximately 800,000 patients were treated suc-
cessfully with Sofosbuvir. 
A LONG WAY TO GO FOR REDUCING HCV 
RELATED MORTALITY 
It is certainly great news since so many patients have bene-
fited from this highly accoladed achievements with an ap-
proved drug on the market. Given the high efficacy and 
safety of the newly developed therapy, it would be ideal to 
treat all patients with chronic HCV infection. It is rather 
challenging for global accessibility to all the people in 
needs due to the high pricing. In addition, while the Sofos-
buvir based therapy is highly effective in clearing the virus 
from the body, that may not translate into an immediate 
effect on lowering the overall disease burden from the pub-
lic health point of view.   
Clearing the virus at a late stage may not be able to halt 
the progression to cirrhosis and hepato-carcinoma. In addi-
tion, there were observations that successful elimination of 
HCV can reactivate hepatitis B virus (HBV) and could po-
tentially worsen the liver disease in patients with HBV and 
HCV co-infections. Furthermore, a WHO report showed 
that the curve in “HBV+HCV” related mortality does not 
bend until 2020. “Globally, less than 5% of persons living 
with chronic viral hepatitis are aware of their status”, ac-
cording to the WHO report (WHO reference number: 
WHO/HIV/2016.06, Global health sector strategy on viral 
hepatitis, 2016-2021(http://www.who.int/hepatitis/strategy 
2016-2021/ghss-hep/en/)). Therefore, it is highly desirable 
to develop efficacious screening program to call for aware-
ness and treatment. Vaccination, currently available against 
hepatitis A, B and E, is most effective way to control the 
virus infection, however, all the efforts on a HCV vaccine 
development failed so far. In the long run, it is desirable to 
prevent the HCV infection among general population via 
vaccination although the mortality of HCV is expected to 
decrease thanks to the availability of the effective therapy. 
CONCLUDING REMARKS 
In about 25 years span from the discovery of the virus 
causing hepatitis C in 1989 to the 2013 approval of Sofos-
buvir, an effective drug for its treatment, the progress to-
wards a hepatitis C cure was remarkable. What we can learn 
from this process is the effective and timely combination 
and integration of disciplines such as basic science in mo-
lecular biology, drug design and development, clinical ob-
servations and clinical trials, etc. Millions of lives have 
been benefited by the effective treatments thanks to the ex-
ceptional accomplishments of this year’s Lasker Awardees, 
Bartenschlager, Rice and Sofia. Enabling tools like the 
functional HCV replicons are the goals for scientists work-
ing on other human pathogens such as HBV. The success of 
the prodrug approach of Sofosbuvir witnesses the power of 
harnessing the intrinsic metabolic machinery for achieving 
the targeted therapy with molecules of high specificity, en-
couraging future rational design of functional biomolecules 
with targeted delivery and desired metabolic destination.  
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